查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945069

产品类型、患者年龄层、严重程度等级、通路和最终用户分類的肥胖症诊断和治疗市场-全球预测，2026-2032年

Obesity Diagnosis & Treatment Market by Product Category, Patient Age Group, Severity Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肥胖症诊断和治疗市场价值将达到 132 亿美元，到 2026 年将成长至 140.3 亿美元，到 2032 年将达到 208.2 亿美元，年复合成长率为 6.72%。

关键市场统计数据
基准年 2025 132亿美元
预计年份：2026年 140.3亿美元
预测年份 2032 208.2亿美元
复合年增长率 (%) 6.72%

权威框架，阐述当前肥胖症诊断和治疗格局，重点关注临床、商业和医疗服务的关键转折点。

肥胖症已从公共卫生挑战演变为一个复杂的临床和商业性领域，涉及诊断、治疗和护理服务模式的交汇点。临床医生、支付方、医疗设备製造商、数位医疗创新者和生命科学公司如今身处一个快速变化的生态系统中，该生态系统受到新型药物疗法、先进治疗技术和不断扩展的远距远端医疗工具的影响。本导言概述了当前的环境，并整合了决策者关注的关键驱动因素：临床疗效、报销途径、监管政策的清晰度、病人参与以及慢性病护理的经济性。

临床突破、日益成熟的数位技术和不断演变的政策如何汇聚，从根本上重塑肥胖症治疗路径和市场竞争

由于技术、临床和政策三大力量的融合，肥胖症的诊断和治疗格局正在改变。这正在重新定义治疗路径和竞争格局。在临床上，强效药物疗法的兴起正在改变治疗流程，并促使人们重新评估传统的手术适应症标准。这些药物为以前缺乏有效药物治疗的患者提供了更多选择，从而改变了转诊模式和适合接受介入治疗的患者群体。同时，医疗设备的创新，例如内视镜袖状胃切除术、胃内球囊和神经调控装置，正在扩大微创手术的范围，并创建结合手术和药物治疗的混合治疗模式。

评估近期美国关税变化如何影响肥胖治疗产业中各相关人员的供应链、采购决策和成本管理

美国近期关税调整和贸易政策变化对肥胖症诊断和治疗产业的供应链决策和成本结构产生了重大影响。对于内视镜袖套、胃内球囊和神经调控系统等医疗设备製造商而言，不断变化的关税政策迫使他们重新评估製造地和筹资策略，以维持利润率。这些压力促使他们采取短期营运应对措施，例如重新安排零件运输路线、重新谈判供应商合同，以及在某些情况下，将最终组装业务迁址，以降低关税风险。

综合細項分析洞察，将产品类型、通路、临床最终用户、患者人口统计特征和基于严重程度的治疗路径联繫起来

细分市场分析揭示了透过产品类型、分销管道、终端用户画像、患者年龄层和疾病严重程度分级来开拓市场时所面临的明确机会和执行挑战。按产品类型划分，数位健康解决方案包括行动应用程式、线上指导和远端医疗服务，这些服务能够实现可扩展的病人参与和远端监测。同时，医疗设备提供内视镜袖状胃切除术、胃内球囊和神经调节装置等选择，为患者提供微创治疗方案，以取代传统手术。营养补充品涵盖膳食纤维补充剂、草药和蛋白质补充剂，可作为行为和药物介入的辅助手段。药物主要集中于Amylin类似物和GLP-1促效剂，这些药物重新定义了药物治疗模式。外科手术包括可调式胃束带术、胆胰分流术、胃绕道术和袖状胃切除术，对于病情较重和合併特定疾病的患者仍然至关重要。

区域策略重点和市场进入差异会影响美洲、欧洲、中东和非洲以及亚太地区的采用和商业化。

区域趋势差异显着，对新参与企业和现有企业都产生了策略性影响。在美洲，医疗支付者和私人医疗机构正迅速采用药物创新，同时在门诊中心和医院扩大外科手术能力，这得益于强大的临床试验网络和私营部门对数位医疗平台的积极投资。欧洲、中东和非洲地区（EMEA）环境复杂多样，监管环境、报销结构以及专业医疗设施的可近性在不同地区差异显着。相关人员必须认真考虑不同的支付方环境和区域卓越中心，这些因素将影响外科手术和器械解决方案的地域渗透率。亚太地区的特点是都市化和生活方式改变推动了需求的快速增长，同时，对远端医疗和可扩展的体重管理项目的投资也在不断增加，这些项目能够服务于庞大且多元化的人群。

竞争与合作并存的企业行为正在塑造製药、医疗设备和数位领域的创新、证据产生和整合式医疗服务。

在肥胖症诊断和治疗领域，主要企业的发展趋势反映出强烈的创新精神、策略联盟和产品组合多元化，各公司都在寻求利用药物、医疗设备和数位化带来的机会。领先的製药创新者正优先进行强有力的临床项目和真实世界证据研究，以证明其药物的长期代谢获益和心血管安全性，这将有助于与支付方进行谈判并最终纳入药品目录。医疗设备製造商正投资于内视镜和神经调控平台的迭代设计改进，以提高病患舒适度、缩短手术时间，并将应用范围扩展到三级医疗中心以外的地区。他们通常与临床专家合作，以加速产品推广应用并完善治疗通讯协定。

产业领导者可采取切实可行的策略重点，以加速技术应用、建立具有韧性的供应链，并产生符合支付方预期的证据。

产业领导者必须采取果断行动，确保在优先考虑永续可及性和公平医疗服务的同时，掌握临床相关性和商业性机会。首先，企业应透过进行纵向结果研究和真实世界证据项目，使临床开发与支付方的证据需求保持一致，以证明持续的体重减轻、代谢改善和医疗资源利用方面的益处。这种方法将加强与支付方的谈判，并支持基于价值的合约。其次，企业应推行整合产品策略，将药物疗法、器材选择和数位化互动平台结合，建构端到端的医疗服务路径。此类整合解决方案将提高患者的用药依从性，并提供与单一疗法竞争对手的有力竞争优势。

一套稳健的多源调查方法，整合了临床证据、相关人员访谈和供应链分析，以检验策略见解。

本分析的调查方法结合了系统性的证据综合、专家访谈和跨部门检验，旨在得出反映临床、商业性和政策现实的可操作性见解。此方法首先对同侪审查的临床文献、监管申报文件、指导文件和公共临床试验註册库进行系统性回顾，以确定药物、手术创新和器械技术的临床有效性和安全性。此外，也透过检验医疗系统指南、支付方政策声明和报销框架，进一步了解医疗服务取得和合约签订趋势。

一项综合分析强调，要使肥胖治疗产生长期影响，需要整合证据、增强运作韧性并制定因地制宜的策略。

分析结论指出，肥胖症的诊断和治疗生态系统正处于转折点，其特征是药物学、器械干预和数位化医疗模式的融合创新。这些趋势正在创建新的临床路径，拓展治疗选择，并促进临床医生、製造商和数位医疗服务提供者之间的跨学科合作。支付方和医疗系统越来越要求提供长期获益和成本效益的证据，这使得製造商和服务提供者有责任提供严谨的疗效数据和切实可行的交付模式。因此，那些将强大的循证能力、整合的医疗服务和稳健的营运策略相结合的机构将主导市场变革并维持市场份额。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依产品类型的肥胖症诊断与治疗市场

  • 数位健康解决方案
    • 行动应用
    • 线上辅导
    • 远端医疗服务
  • 医疗设备
    • 内视镜袖状胃成形术
    • 胃内球囊
    • 神经调控装置
  • 营养补充品
    • 膳食纤维补充剂
    • 草药补充剂
    • 蛋白质补充剂
  • 製药
    • Amylin类似物
    • GLP-1促效剂
  • 外科手术
    • 可调式胃束带
    • 胆胰分流术
    • 胃绕道手术
    • 袖状切除术

9. 按患者年龄层分類的肥胖症诊断与治疗市场

  • 成人版
  • 老年人
  • 儿童

第十章 依严重程度分類的肥胖症诊断与治疗市场

  • 一级
  • 二类
  • 三级

第十一章 按分销管道分類的肥胖症诊断和治疗市场

  • 医院药房
  • 网路药房
  • 零售药房
  • 专业诊所频道

第十二章 依最终使用者分類的肥胖症诊断与治疗市场

  • 门诊手术中心
  • 诊所
  • 家庭医疗保健
  • 医院

第十三章 各地区的肥胖诊断与治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的肥胖症诊断与治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国肥胖症诊断与治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肥胖症诊断与治疗市场

第十七章 中国肥胖症诊断与治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Apollo Endosurgery, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gelesis, Inc.
  • GlaxoSmithKline plc
  • Herbalife Nutrition Ltd.
  • Johnson & Johnson Services, Inc.
  • Larimar Therapeutics, Inc.
  • Medifast, Inc.
  • Medtronic PLC
  • Novo Nordisk A/S
  • NutriSystem, Inc.
  • Olympus Corporation
  • Pfizer, Inc.
  • ReShape Lifesciences Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vivus, Inc.
Product Code: MRR-8D2A8050FA72

The Obesity Diagnosis & Treatment Market was valued at USD 13.20 billion in 2025 and is projected to grow to USD 14.03 billion in 2026, with a CAGR of 6.72%, reaching USD 20.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.20 billion
Estimated Year [2026] USD 14.03 billion
Forecast Year [2032] USD 20.82 billion
CAGR (%) 6.72%

An authoritative framing of the current obesity diagnosis and treatment landscape highlighting clinical, commercial, and care-delivery inflection points

Obesity has evolved from a public health challenge to a complex clinical and commercial landscape where diagnostics, therapeutics, and care delivery models intersect. Clinicians, payers, device manufacturers, digital health innovators, and life-science companies now operate within a fast-moving ecosystem shaped by novel pharmacotherapies, rising procedural sophistication, and an expanding array of remote care tools. This introduction frames the current environment by synthesizing drivers that matter to decision-makers: clinical efficacy, reimbursement pathways, regulatory clarity, patient engagement, and the economics of chronic care.

Across care settings, advances in pharmacology-most notably incretin-based agents-have catalyzed renewed attention to medical management, while emergent technologies in endoscopic and neuromodulation devices present alternatives or complements to surgical approaches. Simultaneously, digital health solutions including mobile applications, telehealth services, and online coaching are reshaping patient monitoring and adherence interventions, creating continuous touchpoints that extend beyond episodic encounters. These developments occur against a backdrop of increasing emphasis on integrated care pathways, where multidisciplinary teams and ambulatory centers play a larger role in delivering tailored interventions.

Policy shifts and payer interest in long-term outcomes reinforce a movement toward value-based care models that prioritize sustained weight reduction and comorbidity improvement rather than short-term metrics alone. In this context, stakeholders must weigh clinical innovation against access constraints and implementation complexity. The introduction sets the stage for deeper exploration of market dynamics, strategic inflection points, and pragmatic considerations for organizations seeking to navigate the rapidly changing obesity diagnosis and treatment environment.

How clinical breakthroughs, digital maturation, and policy evolution are converging to fundamentally reshape obesity care pathways and market competition

The landscape of obesity diagnosis and treatment is undergoing transformative shifts driven by converging technological, clinical, and policy forces that are redefining care pathways and competitive positioning. Clinically, the rise of potent pharmacotherapies has altered treatment algorithms and stimulated re-evaluation of traditional surgical thresholds; these agents are expanding options for patients who previously lacked viable medical alternatives, thereby changing referral patterns and the composition of candidates for invasive procedures. At the same time, device innovation in endoscopic sleeve techniques, intragastric balloons, and neuromodulation devices is broadening the spectrum of minimally invasive interventions, creating hybrid care models that blend procedural and medical management.

On the digital front, mobile applications, telehealth services, and online coaching platforms have matured from engagement-focused adjuncts into core components of chronic disease management, enabling continuous monitoring, remote titration of therapies, and improved adherence. This digital maturation facilitates earlier diagnosis through remote screening tools and enhances long-term follow-up. From a systems perspective, payers and health systems are increasingly focused on outcome-driven contracts, pressuring manufacturers and providers to demonstrate sustained weight reduction and comorbidity improvements rather than short-term gains. Regulatory environments are also adapting, with faster review pathways and clearer guidance around novel combination approaches, which reduces time-to-market but raises the bar for robust lifecycle evidence.

Collectively, these shifts compel stakeholders to adopt integrated strategies that align product development, clinical evidence generation, and reimbursement planning. Organizations that invest in cross-functional capabilities-combining digital engagement, robust real-world evidence programs, and adaptive commercialization models-will be better positioned to capitalize on the sector's dynamic transformation.

Assessment of how recent United States tariff changes are reshaping supply chains, sourcing decisions, and cost management across obesity treatment stakeholders

Recent tariff adjustments and trade policy developments in the United States have materially influenced supply chain decisions and cost structures across the obesity diagnosis and treatment landscape. For manufacturers of medical devices such as endoscopic sleeves, intragastric balloons, and neuromodulation systems, shifting tariff schedules have necessitated reevaluation of manufacturing footprints and sourcing strategies to protect margin integrity. These pressures prompt near-term operational responses including re-routing of components, renegotiation of supplier contracts, and, in select cases, relocation of final assembly to mitigate tariff exposure.

Pharmaceutical supply chains have also felt the impact, particularly where active pharmaceutical ingredients or finished products move across borders. Organizations have increased emphasis on supply diversification, multi-sourcing, and strategic stockpiling to avoid disruption to therapeutic availability. For digital health companies and software-centric solutions, the tariff impact is comparatively indirect but still relevant where hardware peripherals or integrated devices are sourced internationally. Distribution channels have responded by reassessing landed costs and adjusting pricing strategies for hospital pharmacies, retail outlets, online pharmacies, and specialty clinics to maintain competitiveness while preserving access.

In response, stakeholders must balance cost mitigation with continuity of care. Health systems and payers are likely to scrutinize cost-pass-throughs and seek contractual protections in supplier agreements. Longer term, tariffs may accelerate onshoring or nearshoring initiatives for critical components, while increasing collaboration between manufacturers and distributors to maintain stable supply. The net effect is a market environment where strategic supply chain resilience becomes a core competency for organizations operating in obesity diagnosis and treatment.

Comprehensive segmentation-driven insights linking product types, distribution pathways, clinical end users, patient demographics, and severity-driven care pathways

Segmentation analysis reveals distinct opportunities and execution challenges when viewing the market through product categories, distribution channels, end-user profiles, patient age groups, and severity classes. When organized by product category, digital health solutions encompass mobile applications, online coaching, and telehealth services that enable scalable patient engagement and remote monitoring, while medical devices include endoscopic sleeve, intragastric balloon, and neuromodulation device options that provide minimally invasive procedural alternatives to traditional surgery. Nutritional supplements span fiber supplements, herbal supplements, and protein supplements that serve as adjuncts to behavioral and medical interventions. Pharmaceuticals are concentrated in amylin analogues and GLP-1 agonists that have redefined pharmacologic treatment paradigms. Surgical procedures include adjustable gastric banding, biliopancreatic diversion, gastric bypass, and sleeve gastrectomy that remain essential for patients with advanced severity or specific comorbidity profiles.

Looking across distribution channels, hospital pharmacy, online pharmacy, retail pharmacy, and specialty clinic channels each present unique access and reimbursement dynamics that influence formulary placement, uptake speed, and patient convenience. End users such as ambulatory surgical centers, clinics, home healthcare providers, and hospitals differ in procedural capabilities, staffing models, and capital requirements, which in turn affects where particular interventions are most effectively deployed. Patient age group segmentation-adult, geriatric, and pediatric-necessitates tailored clinical approaches, dosing strategies, and patient engagement techniques, with pediatrics requiring additional focus on family-centered care and long-term behavioral supports. Severity class segmentation across Class I, Class II, and Class III obesity demands calibrated clinical pathways; for example, moderate cases may benefit most from pharmacotherapy combined with digital coaching, whereas advanced cases often require multidisciplinary evaluation and procedural options. Integrating these segmentation lenses allows stakeholders to refine product positioning, prioritize channels for commercial outreach, and design evidence generation programs that align with the specific needs of each subpopulation.

Regional strategic imperatives and market access variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that affect adoption and commercialization

Regional dynamics vary significantly and shape strategic imperatives for market entrants and incumbents alike. In the Americas, healthcare payers and commercial providers have rapidly adopted pharmacologic innovations alongside expanded procedural capacity in ambulatory centers and hospitals, supported by strong clinical trial networks and active private sector investment in digital health platforms. Europe, Middle East & Africa presents a heterogeneous environment where regulatory frameworks, reimbursement systems, and access to specialized centers vary widely; stakeholders must navigate diverse payer landscapes and regional centers of excellence that influence where surgical and device-based solutions gain traction. Asia-Pacific is characterized by rapidly growing demand driven by urbanization and changing lifestyle patterns, concurrent with expanding investments in telehealth and scalable weight management programs that can address large, diverse populations.

Each region's distribution infrastructure and channel preferences differ, with hospital and specialty clinic channels dominating in settings where procedural capacity is concentrated, while online pharmacies and telehealth-led services proliferate where digital adoption and regulatory allowances enable remote care. Cross-border regulatory harmonization and partnerships with local clinical networks are critical enablers in Europe, Middle East & Africa and parts of Asia-Pacific, whereas the Americas often emphasize outcomes-based contracting and private payer negotiations. These regional distinctions necessitate tailored market entry strategies, localized evidence generation, and partnerships that align with regional reimbursement policies and clinical referral patterns. Consequently, firms should align commercialization tactics with the specific regulatory, payer, and care-delivery realities of each macro region to accelerate adoption and ensure sustained patient access.

Competitive and collaborative company behaviors shaping innovation, evidence generation, and integrated care offers across pharmacologic, device, and digital players

Key company dynamics in obesity diagnosis and treatment reflect intense innovation, strategic collaborations, and portfolio diversification as firms seek to capture opportunities across pharmacologic, device, and digital domains. Leading pharmaceutical innovators have prioritized robust clinical programs and real-world evidence initiatives to demonstrate long-term metabolic benefits and cardiovascular safety, which supports payer negotiations and formulary inclusion. Device manufacturers are investing in iterative design improvements for endoscopic and neuromodulation platforms to enhance patient comfort, reduce procedural time, and broaden applicability beyond tertiary centers, often collaborating with clinical leaders to accelerate adoption and refine procedural protocols.

Digital health companies are increasingly forming partnerships with pharmaceutical and device firms to create integrated care pathways that combine pharmacotherapy, remote monitoring, and behavioral coaching, thereby strengthening adherence and outcomes. Meanwhile, distributors and specialty clinics are evolving their service offerings to incorporate bundled care delivery models that combine diagnostics, therapy initiation, and follow-up, improving patient retention and value demonstration. Across these movements, mid-size innovators and niche players play an important role by converging targeted technologies-such as adjunct nutritional supplements or focused telehealth solutions-into broader care ecosystems. Competitive differentiation increasingly stems from the ability to generate comprehensive evidence packages, demonstrate interoperability with electronic health records and remote monitoring tools, and negotiate innovative reimbursement arrangements that align incentives between manufacturers, providers, and payers.

Actionable strategic priorities for industry leaders to accelerate adoption, build resilient supply chains, and align evidence generation with payer expectations

Industry leaders must act decisively to capture clinical relevance and commercial opportunity while prioritizing sustainable access and equitable care. First, organizations should align clinical development with payer evidence needs by building long-term outcome studies and real-world evidence programs that demonstrate durable weight reduction, metabolic improvement, and healthcare utilization benefits. This approach strengthens negotiations with payers and supports value-based contracting. Second, companies should pursue integrated product strategies that combine pharmacologic therapies, device options, and digital engagement platforms to create end-to-end care pathways; such integrated offerings improve adherence and create defensible differentiation against single-modality competitors.

Third, investing in supply chain resilience and flexible manufacturing footprints mitigates tariff and trade risks, while strategic partnerships with regional distributors and specialty clinics optimize market access. Fourth, leaders should prioritize interoperability and data-sharing capabilities to ensure digital tools and monitoring systems integrate seamlessly into provider workflows and electronic health records, enabling scalable care coordination. Fifth, organizations must refine segmentation strategies to target interventions by patient age and severity class, tailoring clinical trial designs and commercial messaging to the needs of adult, geriatric, and pediatric populations as well as Class I through Class III severity strata. Finally, proactive engagement with regulators and payers to clarify evidence requirements and reimbursement models will accelerate adoption. Together, these actions form a pragmatic roadmap for industry leaders to translate innovation into sustained clinical and commercial impact.

Robust multi-source research methodology integrating clinical evidence, stakeholder interviews, and supply chain analysis to validate strategic insights

The research methodology underpinning this analysis combined systematic evidence synthesis, expert interviews, and cross-functional triangulation to produce actionable insights that reflect clinical, commercial, and policy realities. The approach began with a structured review of peer-reviewed clinical literature, regulatory filings, guidance documents, and publicly available clinical trial registries to establish the clinical efficacy and safety profiles of pharmacologic agents, procedural innovations, and device technologies. This literature foundation was augmented by an examination of health system guidance, payer policy statements, and reimbursement frameworks to understand access dynamics and contractual trends.

To contextualize these findings, the research incorporated primary qualitative inputs from clinicians, hospital administrators, device developers, digital health executives, and payer representatives to validate hypotheses and surface implementation barriers. These expert engagements informed assessments of adoption drivers, channel dynamics, and regional nuances. The analysis also examined supply chain structures and tariff impacts by reviewing import data, supplier footprint strategies, and public trade policy disclosures to evaluate operational risks. Finally, insights were synthesized through cross-validation between clinical evidence and market practice, emphasizing pragmatic implications for stakeholders. This multi-source and multi-stakeholder methodology ensures that the conclusions are grounded in both empirical evidence and operational realities, supporting confident strategic decision-making.

Concluding synthesis underscoring the need for integrated evidence, operational resilience, and regionally tailored strategies to realize long-term impact in obesity care

This analysis concludes that the obesity diagnosis and treatment ecosystem is at an inflection point defined by convergent innovations in pharmacology, device-based interventions, and digital care models. These trends create new clinical pathways that expand therapeutic options and invite cross-disciplinary collaboration among clinicians, manufacturers, and digital health providers. Payers and health systems increasingly demand evidence of long-term benefit and cost-effectiveness, which shifts the burden to manufacturers and providers to supply rigorous outcome data and practical delivery models. Consequently, the organizations that combine strong evidence-generation capabilities with integrated care offerings and resilient operational strategies will lead adoption and sustain market relevance.

At the same time, supply chain and trade considerations underscore the importance of operational agility; proactive supply diversification and regional partnerships will be essential to protect access. Segmentation analysis highlights the need for tailored strategies across product types, channels, end users, patient age groups, and severity classes, enabling more precise targeting of clinical programs and commercial investments. Regional variability further emphasizes that a one-size-fits-all approach will underperform; instead, market entry and expansion must be adapted to local regulatory, reimbursement, and care-delivery contexts. In sum, the path forward requires coordinated action across clinical development, commercial execution, and payer engagement to convert innovation into sustained patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Diagnosis & Treatment Market, by Product Category

  • 8.1. Digital Health Solutions
    • 8.1.1. Mobile Applications
    • 8.1.2. Online Coaching
    • 8.1.3. Telehealth Services
  • 8.2. Medical Devices
    • 8.2.1. Endoscopic Sleeve
    • 8.2.2. Intragastric Balloon
    • 8.2.3. Neuromodulation Device
  • 8.3. Nutritional Supplements
    • 8.3.1. Fiber Supplements
    • 8.3.2. Herbal Supplements
    • 8.3.3. Protein Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Amylin Analogues
    • 8.4.2. Glp-1 Agonists
  • 8.5. Surgical Procedures
    • 8.5.1. Adjustable Gastric Banding
    • 8.5.2. Biliopancreatic Diversion
    • 8.5.3. Gastric Bypass
    • 8.5.4. Sleeve Gastrectomy

9. Obesity Diagnosis & Treatment Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Obesity Diagnosis & Treatment Market, by Severity Class

  • 10.1. Class I
  • 10.2. Class II
  • 10.3. Class III

11. Obesity Diagnosis & Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Specialty Clinic Channels

12. Obesity Diagnosis & Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospitals

13. Obesity Diagnosis & Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Obesity Diagnosis & Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Obesity Diagnosis & Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Obesity Diagnosis & Treatment Market

17. China Obesity Diagnosis & Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apollo Endosurgery, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Boehringer Ingelheim International GmbH
  • 18.11. BTL Aesthetics
  • 18.12. C.H. Boehringer Sohn AG & Ko. KG
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. Gelesis, Inc.
  • 18.16. GlaxoSmithKline plc
  • 18.17. Herbalife Nutrition Ltd.
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Larimar Therapeutics, Inc.
  • 18.20. Medifast, Inc.
  • 18.21. Medtronic PLC
  • 18.22. Novo Nordisk A/S
  • 18.23. NutriSystem, Inc.
  • 18.24. Olympus Corporation
  • 18.25. Pfizer, Inc.
  • 18.26. ReShape Lifesciences Inc.
  • 18.27. Sanofi S.A.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MOBILE APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE COACHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY TELEHEALTH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NEUROMODULATION DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY FIBER SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HERBAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PROTEIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMYLIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY BILIOPANCREATIC DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SLEEVE GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLASS III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINIC CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 222. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GCC OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 252. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 255. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. G7 OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 261. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 263. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 266. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DIGITAL HEALTH SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY SEVERITY CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA OBESITY DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)